PDE10A

Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Capital

Retrieved on: 
Tuesday, March 7, 2023
Depression, Noema, Tourette syndrome, Stuttering, Investment, Polaris Partners, INVU (song), PDE10A, Glutamate (neurotransmitter), CHF, Myenteric plexus, Trigeminal neuralgia, Tuberous sclerosis complex tumor suppressors, CNS, Knowledge, Pain, Research, Seizure, Drug development, TSC, Patient, Sofinnova, News, Series, Central nervous system disease, General partnership, Atypical depression, COFD, Pharmaceutical industry

The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital.

Key Points: 
  • The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital.
  • Following the close of the Series B financing, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the Board of Directors of Noema Pharma.
  • USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners.
  • Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.

Noema Pharma, Founded by Sofinnova Partners, Raises CHF 103 Million (USD 112 Million) in Series B Financing

Retrieved on: 
Tuesday, March 7, 2023
Other Professional Services, Biotechnology, Pharmaceutical, Finance, General Health, Health, Professional Services, Clinical Trials, Polaris Partners, PDE10A, Partner, Atypical depression, Series A round, Tuberous sclerosis complex tumor suppressors, Sofinnova, News, COFD, CHF, Central nervous system disease, Patient, INVU (song), Tourette syndrome, TSC, Glutamate (neurotransmitter), CNS, Pain, Depression, Series, Seizure, Stuttering, Trigeminal neuralgia, Pharmaceutical industry, Noema

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx.

Key Points: 
  • Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx.
  • This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
    The Series B financing follows a CHF 54 million (approx.
  • USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners.
  • Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.

EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury

Retrieved on: 
Wednesday, February 15, 2023
Brain, PDE10A, Therapy, NMDAR, DSM-IV codes, Traumatic brain injury, Tourette syndrome, Patient, File, ASD, Spectrum, Quality of life, TS, IND, Pharmaceutical industry

EuMentis is in active discussion with other investors to complete its Series B round.

Key Points: 
  • EuMentis is in active discussion with other investors to complete its Series B round.
  • The complete Series B financing will enable EuMentis to conduct an additional randomized, placebo-controlled Phase 2 clinical trial of EM-221, its best-in-class PDE10A inhibitor, in TS patients.
  • We believe that EuMentis’ novel therapies have the potential to dramatically improve the quality of life of patients suffering from autism, Tourette syndrome and traumatic brain injury, and other serious neuropsychiatric and neurodevelopment conditions.
  • We likewise look forward to advancing EM-221 into a randomized, placebo-controlled Phase 2 clinical study for Tourette syndrome with additional Series B capital.”

Noema Pharma Receives FDA Fast Track Designation for basimglurant (NOE-101) in Trigeminal Neuralgia

Retrieved on: 
Tuesday, October 18, 2022
Physician, Tourette syndrome, Disease, Columbia University Irving Medical Center, Review, IND, Tuberous sclerosis complex tumor suppressors, US Foods, Glutamate (neurotransmitter), PDE10A, Trigeminal nerve, Patient, Investigational New Drug, Pain management, Seizure, Addiction medicine, Food, Trigeminal neuralgia, Neurology, Company, Basimglurant, Sofinnova, Pain, Face, Safety, Adult, Neuropathic pain, CNS, GLOBE, Fast Track, Brain, Polaris Partners, FDA, Principal, Pharmaceutical industry, Anesthesia, Biotechnology

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia (TN).

Key Points: 
  • BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia (TN).
  • "We are very pleased to receive Fast Track designation from the FDA, which is intended to bring promising medicines to patients sooner, and very much underlines the potential of basimglurant in pain management associated with TN," said George Garibaldi MD, President, Head of R&D of Noema Pharma.
  • The FDA authorized Noema Pharma's Investigational New Drug (IND) application to initiate a Phase 2/3 clinical trial of basimglurant in TN in February 2022.
  • Basimglurant, an mGluR5 inhibitor, is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex and severe pain in Trigeminal Neuralgia.

Royalty Pharma Announces R&D Funding Collaboration With Merck

Retrieved on: 
Wednesday, October 12, 2022
MSD, U.S. Securities and Exchange Commission, Sale, Royalty Pharma, Merck & Co., AbbVie, Schizophrenia, Fenwick & West, PDE10A, Patient, Publication, Research, Nasdaq, Private Securities Litigation Reform Act, Industry, Armin Maiwald, GLOBE, Forward-looking statement, EDGAR, Terminology, Pharmaceutical industry, Fine chemical, Merck, Neuroscience, Ivacaftor

This creative agreement is a great example of how Royalty Pharma provides innovative, win-win funding solutions and supports exciting medicines like MK-8189 across the biopharma industry.

Key Points: 
  • This creative agreement is a great example of how Royalty Pharma provides innovative, win-win funding solutions and supports exciting medicines like MK-8189 across the biopharma industry.
  • Royalty Pharma sees an exciting future opportunity to partner with Merck and other global pharmaceutical companies on drug development.
  • Under the agreement Royalty Pharma will provide $50 million upfront to Merck to support ongoing development of MK-8189.
  • We look forward to progressing the development of MK-8189 by means of this creative agreement with Royalty Pharma.

Noema Pharma Announces Completion of Enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) Validation Study

Retrieved on: 
Tuesday, September 6, 2022
Trigeminal nerve, UCL, University College Hospital, Pain, Trigeminal neuralgia, Noema, Sofinnova, Glutamate (neurotransmitter), Seizure, Brain, LIBRA, Sensation, Diagnosis, Self-assessment, Pain scale, Neuropathic pain, GLOBE, Â, Nerve injury, Company, Diary, Tourette syndrome, Data collection, Face, PDE10A, Polaris Partners, CNS, UCLH, Tuberous sclerosis complex tumor suppressors, Patient, Basimglurant, Medical device, Pharmaceutical industry, Research, Biotechnology

BASEL, Switzerland and BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces it has completed participant enrollment and data collection in the validation study of a novel Trigeminal Neuralgia Electronic Diary (TNED).

Key Points: 
  • BASEL, Switzerland and BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces it has completed participant enrollment and data collection in the validation study of a novel Trigeminal Neuralgia Electronic Diary (TNED).
  • Thirty participants with a confirmed diagnosis of trigeminal neuralgia (TN) volunteered to complete the electronic diary.
  • While the analysis of the validation data is ongoing, the electronic diary was generally found to be easy to use and enabled participants to accurately describe the burden of trigeminal neuralgia (TN).
  • In addition to being patient friendly and easy to use, TNED is the first electronic diary designed specifically for people who suffer from TN.

Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder

Retrieved on: 
Thursday, August 4, 2022
People, Orpheus, Disorder, Tuberous sclerosis complex tumor suppressors, Disability, Glutamate (neurotransmitter), Patient, Stuttering, Company, Neurodevelopmental disorder, CNS, Pain, Safety, FDA, Seizure, Adolescence, Solution, Work, Insulin resistance, GLOBE, PDE10A, Person, Sofinnova, Central nervous system, Â, Neuron, Trigeminal neuralgia, Tourette syndrome, Employment, Ageing, Polaris Partners, Basimglurant, COFD, Population, Pharmaceutical industry, Biotechnology, MD

Orpheus is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.

Key Points: 
  • Orpheus is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.
  • "Recruiting the first participant is an important step in the clinical investigation of gemlapodect in this indication.
  • "Our main goal is to evaluate the safety and efficacy of gemlapodect as a monotherapy for COFD in adults.
  • Gemlapodect, a PDE10A inhibitor, is currently enrolling a Phase 2a clinical trial in patients with Tourette Syndrome.

Noema Pharma Announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b Study of PDE10A Inhibitor Gemlapodect (NOE-105) in Childhood Onset Fluency Disorder

Retrieved on: 
Monday, June 27, 2022
People, Efficiency, FDA, Patient, Sofinnova, Glutamate (neurotransmitter), Basimglurant, Neurodevelopmental disorder, Polaris Partners, TSC, Biology, Investigational New Drug, GLOBE, CNS, Company, Orpheus, PDE10A, Trigeminal neuralgia, Ageing, Disorder, IND, Disability, Neuron, Seizure, COFD, Tuberous sclerosis complex tumor suppressors, US Foods, Tourette syndrome, Safety, Insulin resistance, Work, Pharmaceutical industry, Noema, Biotechnology, Stuttering, Research, MD

The Orpheus Phase 2b study is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.

Key Points: 
  • The Orpheus Phase 2b study is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.
  • "We have great confidence that gemlapodect will help people who stutter maximize their ability to live life to the fullest."
  • Noema Pharma ( www.noemapharma.com ) is a clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications characterized by imbalanced neuronal networks.
  • Gemlapodect, a PDE10A inhibitor, is currently enrolling a Phase 2a clinical trial in patients with Tourette Syndrome.

Noema Pharma to Attend and Present at BioEquity Europe and UBS Global Healthcare Conference in May 2022

Retrieved on: 
Friday, May 6, 2022
EDT, Tourette syndrome, Biotechnology, Sofinnova, GLOBE, CNS, Polaris Partners, Company, Tuberous sclerosis complex tumor suppressors, Trigeminal neuralgia, Patient, Seizure, Glutamate (neurotransmitter), TSC, CEST, PDE10A, Pharmaceutical industry

Presentation on Wednesday 25 May at 1:15 pm EDT / 7:15 pm CEST.

Key Points: 
  • Presentation on Wednesday 25 May at 1:15 pm EDT / 7:15 pm CEST.
  • Noema Pharma ( www.noemapharma.com ) is a Swiss clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications characterized by imbalanced neuronal networks.
  • Noema Pharma was founded with the leading venture capital firm Sofinnova Partners.
  • Investors include Polaris Partners, Gilde Healthcare, Invus and Biomed Partners.

Noema Pharma to Attend and Present at Stifel 2022 CNS Days

Retrieved on: 
Friday, March 25, 2022
Trigeminal neuralgia, Company, Tourette syndrome, Seizure, Lists of diseases, Sofinnova, CNS, Tuberous sclerosis complex tumor suppressors, Glutamate (neurotransmitter), PDE10A, TSC, GLOBE, Polaris Partners, Patient, Pharmaceutical industry, Noema

BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous system (CNS) diseases, today announces it will participate in the Stifel 2022 CNS Days conference, being held virtually from March 28 to 29, 2022.

Key Points: 
  • BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous system (CNS) diseases, today announces it will participate in the Stifel 2022 CNS Days conference, being held virtually from March 28 to 29, 2022.
  • Management will also present the latest development of Noema to investors and will host 1:1 investor meetings.
  • Noema Pharma ( www.noemapharma.com ) is a Swiss-based company targeting neurological disorders characterized by imbalanced neuronal networks.
  • Noema Pharma was founded with the leading venture capital firm Sofinnova Partners.